Investing Profile

Josh Bilenker

VC

Photo of Josh Bilenker, Partner at Aisling Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
Aisling Capital Partner
15
$280M
CompanyStageDateRound SizeTotal Raised
ViewRay
Post-IPO EquityJul 2015$27M
Venture RoundDec 2013$30M
Venture RoundMay 2013$15M
Series CMar 2012$45M
Debt FinancingSep 2011$10M
Series CAug 2010$20M
$150M
LensAR
Private Equity RoundJan 2015$16M
Debt FinancingOct 2013$60M
Private Equity RoundOct 2013$27M
Venture RoundMar 2012$24M
$130M
Loxo Oncology
Series BMay 2014$24M
$57M
Co-investors: Dov Goldstein (Aisling Capital), David Bonita (OrbiMed), James Barrett
T2 Biosystems
Series EMar 2013$40M
Series DAug 2011$23M
$95M
Co-investors: Alan Crane (Polaris Partners), Michael Greeley (Flare Capital Partners), Harry Wilcox (Flagship Pioneering), Stacy Feld (Johnson & Johnson Innovation)
Aragon Pharmaceuticals
Series DOct 2012$50M
$80M
Co-investors: Brett Zbar (Foresite Capital), Carl Gordon (OrbiMed), Peter Svennilson (The Column Group)
Roka Bioscience
Series DJan 2012$48M
$68M
Co-investors: Jonathan Silverstein (OrbiMed Advisors), James Barrett